LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Snibe Diagnostic’s Maglumi SARS-CoV-2 S-RBD IgG Test Receives CE Mark

By LabMedica International staff writers
Posted on 05 Aug 2020
Print article
Image: Snibe Diagnostic’s Maglumi SARS-CoV-2 S-RBD IgG Test (Photo courtesy of Snibe Diagnostic)
Image: Snibe Diagnostic’s Maglumi SARS-CoV-2 S-RBD IgG Test (Photo courtesy of Snibe Diagnostic)
Snibe Diagnostic (Shenzhen, China) has received the CE mark for its fully automated quantitative serology test for detecting IgG antibodies against SARS-CoV-2S-RBD, the receptor-binding domain of S protein.

The test, called Maglumi SARS-CoV-2 S-RBD IgG, is designed for the quantitative detection of antibodies to the receptor-binding domain of the S protein, which are believed to neutralize the coronavirus and are an effective measure of immunity as compared to antibodies that target other SARS-CoV-2 proteins. According to Snibe, the test has 99.6% specificity and 100% sensitivity at 15 days following the onset of symptoms for COVID-19, thus providing more accurate results. A strong correlation to neutralizing antibodies ensures better clinical management.

The test can be run on the company’s Maglumi CLIA systems, including the Maglumi X8 immunoassay analyzer which can run up to 600 tests per hour. More than 13,000 Maglumi CLIA system installations across the world pave the way for wide availability of the test. Snibe has confirmed that it is ready to ship the Maglumi SARS-CoV-2 S-RBD IgG test worldwide.

Related Links:
Snibe Diagnostic

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.